Bone Marrow News and Research

RSS

Bone Marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.

Mutation causing light chain amyloidosis identified

Light chain amyloidosis, a deadly protein misfolding disease, is caused by multiple mutations in cells that are intended to protect the body. Instead, the mutations send misfolded bundles of proteins through the bloodstream, potentially destroying the heart, kidneys, liver or other organs. Mayo Clinic researchers have identified one of these mutations and have shown that the molecule's shifting position is as important as its unique shape. The findings appear in the current issue of the journal Structure.

12 May 2010

Benefits outweigh risks in myeloablative therapy for children with high-risk neuroblastoma

Neuroblastoma is among the most common of childhood cancers and fortunately, some children will get better spontaneously. Yet for children with high-risk disease the outlook is poor: more than half will relapse despite chemotherapy.

12 May 2010

Researchers develop anti-angiogenic molecule SR16388 for treatment of MM

SRI International, an independent nonprofit research and development organization, announced today that researchers have developed an anti-angiogenic molecule SR16388 that has demonstrated preclinical antitumor activity against multiple myeloma.

12 May 2010

Beike Biotechnology, Jiangsu government's CMC open world's largest stem cell management center

Beike Biotechnology Co. Ltd., one of the world's leading biotechnology companies focusing on adult stem cell therapies, and the Jiangsu government's China Medical City (CMC) opened China's state-of-the-art stem cell storage and processing facility today. The 20,000 square-meter Stem Cell Regenerative Medicine Industrial Project of National Bio-Industry Base (NBPD) houses China's first comprehensive regenerative medicine technology center and its largest international stem cell bank.

12 May 2010

Compugen discovers CGEN-928 as antibody drug target for treatment of multiple myeloma

Compugen Ltd. announced today the discovery and initial experimental validation of CGEN-928 as a drug target for the treatment of multiple myeloma. In recently completed studies, CGEN-928, a membrane protein which previously had no known function or potential clinical utility, demonstrated broad expression in human multiple myeloma tumor cells, including drug resistant and aggressive primary tumor cell lines.

12 May 2010

New multicenter trial achieves 71% survival in AML children

More individualized therapy and better supportive care helped push the survival for children with acute myeloid leukemia (AML) to 71 percent three years after diagnosis, according to new research led by St. Jude Children's Research Hospital investigators and reported in the medical journal The Lancet Oncology. The survival rate of 71 percent is 20 percent better than previously reported U.S. rates and is similar to the success achieved in a 2009 Japanese study, said Jeffrey Rubnitz, M.D., Ph.D., a member of the St. Jude Oncology department.

11 May 2010

Increased cholesterol levels can affect microenvironment of bone marrow

Increased cholesterol levels are being increasingly recognised as risk factors for the onset and progression of several cancers. Now researchers in Portugal show that high levels of cholesterol can affect the microenvironment of the bone marrow, so that more cells move from the bone marrow to peripheral, circulating blood.

11 May 2010

Aastrom Biosciences reports third quarter 2010 FY results

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported financial results for its third fiscal quarter ended March 31, 2010, and also announced progress in its late-stage clinical development programs and corporate operations.

11 May 2010

Advances in combination adult stem cell treatment for acute myocardial infarction presented at SCAI

This week, TCA Cellular Therapy's Medical Director Gabriel Lasala, M.D. presents advances in a proprietary combination adult stem cell treatment for acute myocardial infarction at the Society for Cardiovascular Angiography and Interventions (SCAI) scientific conference in San Diego.

7 May 2010

THI at St. Luke's reveals new insights on how adult stem cells repair damaged hearts following heart attack

Physician scientists at the Texas Heart Institute at St. Luke's Episcopal Hospital (THI at St. Luke's) are publishing research this week that reveals new insights into how a particular set of human adult stem cells helps repair damaged hearts following a heart attack in laboratory mice.

7 May 2010

Mouse study may lead to new therapies for Parkinson's disease

Endometrial stem cells injected into the brains of mice with a laboratory-induced form of Parkinson's disease appeared to take over the functioning of brain cells eradicated by the disease.

7 May 2010

Bioengineers define relationship between key regulatory proteins

With thousands of scientists across the globe searching for ways to use adult stem cells to fight disease, there's a growing emphasis on finding the "master regulators" that guide the differentiation of stem cells. New research from Rice University and the University of Cambridge suggests that a closely connected trio of regulatory proteins fulfills that role in hematopoietic stem cells (HSCs), the self-renewing cells the body uses to make new blood cells.

7 May 2010

Study confirms long-term durability of endoscopic RFA using HALO system for eradicating Barrett's esophagus

Results from two major multi-center clinical trials presented at the Digestive Disease Week in New Orleans independently confirmed that the effects of endoscopic radiofrequency ablation (RFA) for eradicating a pre-cancerous condition of the esophagus called Barrett's esophagus are durable in the long-term. In a plenary scientific presentation titled "Endoscopic Radiofrequency Ablation for Barrett's Esophagus: Five-year Durability Outcomes from a Prospective Multi-Center Trial," patients with Barrett's esophagus were treated with endoscopic RFA using the HALO system.

6 May 2010

Osiris Therapeutics resumes enrollment in Prochymal trial for treatment-resistant Crohn's disease

Osiris Therapeutics, Inc. today announced that it is resuming enrollment in its clinical trial evaluating Prochymal for patients with treatment-resistant Crohn's disease. The findings of an interim analysis showed that for the primary endpoint of disease remission, Prochymal is approaching statistical significance in the intent to treat (ITT) population, and has reached significance in the per protocol population.

6 May 2010

Patients Medical provides patients with valuable tips to prevent Lyme disease

Patients Medical, a leading integrative and holistic medical center in New York City, is supporting National Lyme Disease Awareness month by providing patients with valuable tips to prevent the disease, as well as education on the best treatment options available.

6 May 2010

Bone marrow stem cells show promise in multiple sclerosis

A groundbreaking trial to test bone marrow stem cell therapy with a small group of patients with multiple sclerosis (MS) has been shown to have possible benefits for the treatment of the disease.

6 May 2010

EpiCept provides update on corporate strategy, reports net loss of $4.5M for first-quarter 2010

EpiCept Corporation today announced operating and financial results for the three months ended March 31, 2010, and provided an update with respect to the Company's key business initiatives.

6 May 2010

THI at St. Luke's awarded $1.5M NIH grant for study of stem cells with LVADs for end-stage heart failure

Physician scientists at the Texas Heart Institute at St. Luke's Episcopal Hospital (THI at St. Luke's) have been awarded a grant of almost $1.5 million by the National Institutes of Health for research into treatments for patients with end-stage heart failure that would combine heart-assist devices and adult stem-cell treatments.

6 May 2010

Allos Therapeutics reports net loss of $20.5 million for first-quarter 2010

Allos Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010.

6 May 2010

New test indicates bone marrow cell therapy may benefit MS patients

A groundbreaking trial to test bone marrow stem cell therapy with a small group of patients with multiple sclerosis (MS) has been shown to have possible benefits for the treatment of the disease.

6 May 2010

Bone Marrow News and Research

Further Reading

Mutation causing light chain amyloidosis identified

Benefits outweigh risks in myeloablative therapy for children with high-risk neuroblastoma

Researchers develop anti-angiogenic molecule SR16388 for treatment of MM

Beike Biotechnology, Jiangsu government's CMC open world's largest stem cell management center

Compugen discovers CGEN-928 as antibody drug target for treatment of multiple myeloma

New multicenter trial achieves 71% survival in AML children

Increased cholesterol levels can affect microenvironment of bone marrow

Aastrom Biosciences reports third quarter 2010 FY results

Advances in combination adult stem cell treatment for acute myocardial infarction presented at SCAI

THI at St. Luke's reveals new insights on how adult stem cells repair damaged hearts following heart attack

Mouse study may lead to new therapies for Parkinson's disease

Bioengineers define relationship between key regulatory proteins

Study confirms long-term durability of endoscopic RFA using HALO system for eradicating Barrett's esophagus

Osiris Therapeutics resumes enrollment in Prochymal trial for treatment-resistant Crohn's disease

Patients Medical provides patients with valuable tips to prevent Lyme disease

Bone marrow stem cells show promise in multiple sclerosis

EpiCept provides update on corporate strategy, reports net loss of $4.5M for first-quarter 2010

THI at St. Luke's awarded $1.5M NIH grant for study of stem cells with LVADs for end-stage heart failure

Allos Therapeutics reports net loss of $20.5 million for first-quarter 2010

New test indicates bone marrow cell therapy may benefit MS patients

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News